GCM
ATXS

Graham Capital Management’s Astria Therapeutics ATXS Stock Holding History

Graham Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,841
Closed -$111K – 1290
2025
Q1 		$111K Buy
+20,841
New +$146K ﹤0.01% 1200
2024
Q4 		– Sell
-10,649
Closed -$117K – 1228
2024
Q3 		$117K Sell
10,649
-4,663
-30% -$51.8K ﹤0.01% 991
2024
Q2 		$139K Buy
+15,312
New +$149K ﹤0.01% 908

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Graham Capital Management's ATXS Position: Q2 2025 in Review

Graham Capital Management sold out of Astria Therapeutics (ATXS) in Q2 2025, closing a stake of 20,841 shares — an estimated $111K sold.

Graham Capital Management first reported a position in ATXS in Q2 2024 and held it in 3 quarters. The position peaked at $139K in Q2 2024. 105 funds tracked by Wall St. Rank hold ATXS as of Q2 2025.

  • Graham Capital Management reported no remaining Astria Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Graham Capital Management sold 20,841 Astria Therapeutics shares in Q2 2025, an estimated $111K.
  • Graham Capital Management first reported a position in Astria Therapeutics in Q2 2024 and held it in 3 quarters.
  • Graham Capital Management's Astria Therapeutics position peaked at $139K in Q2 2024.
  • 105 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2025.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.